Macrophages can kill tumor cells by releasing high levels of nitric oxide (NO) and related reactive nitrogen species such as nitroxyl and peroxynitrite, after up-regulation of expression of the inducible nitric oxide synthase gene (iNOS). In this paper we describe two novel human cell lines that are capable of expressing high levels of iNOS under the control of analogues of either the insect hormone ecdysone or tetracycline. We have entrapped these iNOS-expressing cells within a semipermeable alginate-poly-L-lysine membrane as a means of delivery to tumor sites in a nude mouse model. These encapsulated cells can be induced to generate sustainable high concentrations NO and reactive nitrogen species at tumor sites after treatment either with ponasterone A or muristerone A or with doxycycline. Delivery of these iNOS-expressing cells to tumors formed from human ovarian cancer SKOV-3 cells results in 100% killing, whereas treatment of tumors formed from human colon cancer DLD-1 cells results in 54% killing. We show that in these iNOS-expressing cells, tumor killing is associated with concomitant upregulation of the Fas/FasL proteins.
R ecent difficulties with virus-based gene therapy strategies have highlighted the need to explore new approaches for the therapeutic delivery of genes (1) . We are interested in alternatives to conventional virus-based gene therapy, particularly in its application to cancer therapy.
The mammalian immunological defense network is involved in tumor suppression, and macrophages constitute a major part of this network by their capacity on specific activation to destroy selectively a broad range of tumor types. Since Hibbs and colleagues first described the role of nitric oxide (NO) in macrophage cytotoxicity in 1987 (2) , numerous studies have shown that cytokine-activated rodent macrophages can generate large concentrations of NO and related reactive nitrogen species (such as nitroxyl and peroxynitrite radicals) by up-regulation of expression of the inducible nitric oxide synthase gene (NOS2, iNOS) (3) . The resulting NO can kill a range of tumor cells of various histogenetic origins (3) (4) (5) . Different mechanisms have been proposed for the antitumor properties of NO, including loss of a large fraction of the iron pool, inhibition of DNA synthase and its rate-limiting enzyme ribonucleotide reductase, reduced activity of cis-aconitase, reduction of O 2 consumption, and damage of complexes I and II in the mitochondrial electron transport chain and the induction of apoptosis (3) (4) (5) .
Recently, many laboratories have made attempts to transfer iNOS or endothelial NOS cDNA sequences into cancer and other target cells for the purpose of gene therapy. For example, transfection of K-1735 melanoma cells with an iNOS cDNA expression cassette suppresses tumorogenicity and abrogates metastasis in a nude mouse model (6) . Similar results were obtained by transfection with a retroviral iNOS expression construct into human renal carcinoma cells (7) . A major problem with current approaches, however, is that the constitutive expression of NOS in recombinant cells is often toxic. As a consequence of this, NOS transfectants typically have to be cultured under conditions that reduce toxicity (for example, in the continued presence of a NOS inhibitor) or, alternatively, must be capable of relatively low-level NO generation. The problems are further compounded by the requirement of NOS for a panel of essential cofactors, such as tetrahydrobiopterin, which may be missing from the target cell (8) . Also, both retrovirus-and adenovirus-based constructs often have additional immune and safety complications (1) that may limit their use.
To overcome the problems associated with both viral gene delivery and the generation of high concentrations of NO in a cell, we propose an alternative gene delivery process based on microencapsulated recombinant cells capable of expressing a regulated NOS expression cassette.
MATERIALS AND METHODS

Cloning
The muristerone A-inducible cell line EcR293 clone 11 carrying transfected human iNOS cDNA under the control of an ecdysone-inducible promoter was prepared as described previously (9) . The tetracycline-regulated mammalian expression vector pcDNA4/TO (Invitrogen, Carlsbad, CA) was used to generate a human iNOS expression vector. This vector contains the strong human cytomegalovirus immediate-early promoter and two tetracycline operator (TetO2) sites, 5'-TCCCTATCAGTGATAGAGA-3', separated by a 2-bp spacer. Each 19-nucleotide TetO2 sequence serves as the binding site for two molecules of the Tet repressor. To develop tetracycline-inducible NO-generating cell lines, the constructs were transfected into T-Rex-293 cells, which express the Tet repressor from pcDNA6/TR (Invitrogen). Dual selection using Zeocin for the human iNOS gene and blasticidin for the Tet repressor gene was carried out. A panel of 25 cell lines was isolated showing tetracycline-dependent (10 ng/ml) induction of NO.
Nitrite assay and NOS assay
The nitrite concentration in the medium, which is used as a reflection of NO production, was determined by using the Griess reaction (1% sulfanilamide, 0.1% n-1-naphthylene diamine dihydrochloride). Absorbance at 540 nm against a reference 620 nm was measured with sodium nitrite as a standard. Because of the existence of endogenous cofactors and substrates (such as tetrahydrobiopterin) in both EcR293 and T-Rex-293 cells, it was unnecessary to add these components to measure NOS activity. NOS activity was measured in cytosolic extracts on the basis of conversion of 14 C-labeled L-arginine to L-citrulline, using reagents from Cayman (Ann Arbor, MI).
Microencapsulation
For microencapsulation, the inducible NO-generating cells were entrapped within a semipermeable alginate-poly-L-lysine membrane as follows. Cells were harvested with trypsin and then resuspended in a 1.8% sodium alginate solution (Sigma-Aldrich, Dorset, England; filter sterilized through a 0.25-µm membrane) in PBS at between 0.5 and 5 × 10 7 cells/ml. The suspension was placed in a syringe and held 20-40 cm above a beaker containing an excess (100 ml) of stirred ice-cold calcium chloride solution (0.2 M, filter sterilized). The cell suspension was extruded through a 21-gauge needle and droplets were made to fall into the solution of sterilized ice-cold calcium chloride. On contact with the calcium chloride, alginate gel formation is immediate, and the droplets are allowed to gel for between 10 and 30 min. The cells are then suspended for 1-10 min in a solution of a 1:1 mixture of 0.1% poly-L-lysine (Sigma) and 0.18% sodium alginate. The positively charged polylysine complexes with the alginate to form a semipermeable membrane. Immediately after encapsulation and washing, the cells are maintained in Dulbecco's modified Eagle's medium with 10% FBS or PBS before further experimentation.
DAF-2 DA staining
Microencapsulated cells (treated or untreated with ponasterone A from 12 h to 4 days) were loaded with DAF-2 DA (10 µM) for 3 h in PBS with 100 µM L-arginine. The fluorescent images of the microencapsulated cells were captured photographically on a Leica DMIRB inverted microscope with filters set to 450-490 nm excitation and 515-565 nm emission (10) .
Xenograft nude mouse model
Young female adult (6-8 wk) CD1 nu/nu mice from Charles River Laboratories (Kent, UK) were used for the xenograft model. The present studies use two human carcinoma cell lines that produce rapidly growing subcutaneous tumors in nude mice. DLD-1 is a human colon adenocarcinoma cell line; SKOV-3 is an ovarian carcinoma cell line. Both were obtained from American Type Culture Collection (ATCC, Manassas, VA). All cultures were free of mycoplasma. To produce subcutaneous tumors in female CD1 nude mice, suspensions of tumor cells in 1 ml of PBS were mixed with 1 ml of microencapsulated EcR293 clone 11 cells. To induce NO generation, 10 mg of ponasterone A was dissolved in 1 ml of sesame oil. The ponasterone A solution was mixed with the mixture of the tumor cells and encapsulated cells. In control experiments, 1 ml of sesame oil was used in the absence of ponasterone A. A total volume of 300 µl of the cell suspension or mixture was injected (with a 21-gauge needle) subcutaneously into the lateral flank proximal to the midline of the mouse. Each experiment used between 5 and 10 animals. Ponasterone A was given in a single dose.
For tetracycline-inducible NO-generating experiments, Tex293 clone 22 cells were microencapsulated essentially as described above and then injected adjacent to preestablished DLD-1 tumors. NO generation was induced by the administration of 0.5 mg/ml doxycycline in the drinking water in 1% ethanol. In control groups, mice received vehicle alone (1% ethanol).
Western blotting and immunohistochemistry
Western blotting was carried out as previously described (9) . Anti-iNOS polyclonal antibody was raised against the seven C-terminal residues of human iNOS: Cyc-Arg-Nle-Orn-(Ser-LeuGlu-Met-Ser-Ala-Leu). Antibody against α-tubulin was from Insight Biotechnology (London, England). Fas and FasL antibodies were from Transduction Labs (Lexington, KY), and Fas and FasL cDNA probes were from Alexis (San Diego, CA). Promoter activity analysis by transient transfection experiments was as described previously (9) . Nuclear fragmentation was assessed with terminal deoxynucleotide transferase (TdT)-mediated dUTP-biotin nick end-labeling (TUNEL), using the TAC kit (R&D Systems, Minneapolis, MN). For each sample, more than 500 cells were counted, and labeled nuclei were expressed as a percentage of the total number. The Fas[CD95](human):Fc kit (Alexis) was used for FasL-mediated inhibition experiments.
NO sensor measurement in xenograft tumors
The measurement of NO release was performed with the inNO-T nitric oxide measurement system using the amino-700 sensor electrode (Harvard Apparatus, Holliston, MA). The sensor was calibrated by the conversion of nitrite to NO in acidic solution in the presence of iodide ion. The reaction has a ratio of 1:1, such that the amount of NO produced in this reaction is equal to the amount of nitrite added. The in vitro specificity of the sensor to measure NO (and not other species such as ascorbate) was determined in cell-based assays using a culture of tetracyclineinducible NO-generating cells after the addition of 100 µM arginine. The human iNOS-specific inhibitor 1400W (20 µM) was used to inhibit NO production. Following calibration, the sensor was inserted into the tumor, and the output current was monitored and recorded on a Windows 95/98 compatible system using analysis software provided with the inNO probe.
RESULTS
Characterization of NO release by inducible iNOS-expressing microencapsulated cells
As a starting point for this strategy, we cloned a human iNOS cDNA under the control of an ecdysone-inducible promoter and transfected the construct into the human fetal kidney cell line EcR293. This cell line contains the heterodimer retinoid X receptor (RXR) and the ecdysone receptor (EcR) (9) . The resulting transfected cell lines can generate NO in a dose-and timedependent manner after treatment with analogues of the insect hormone ecdysone-muristerone A or ponasterone A (9). Typically, treatment of EcR 293 clone 11 cells with 1 or 10 µM ponasteone A resulted in values for NOS activity of 6 ± 2 and 33 ± 4 pmol/min/mg, respectively. By using dilution cloning, several subclones were isolated that were capable of generating NO at much higher concentrations. One of the subclones (sub-1) can produce up to 45 µM nitrite/10 6 cells after 24 h induction. This induction can be completely inhibited by the NOS inhibitor Niminoethyl-L-ornithine (L-NIO) (20 µM). Treatment of EcR293 clone 11 sub-1 cells with 1 or 10 µM ponasterone A resulted in NOS activity values of 50 ± 10 and 300 ± 40 pmol/min/mg, respectively. This high activity is comparable to the levels of NOS measured in murine macrophages activated by treatment with interferon γ (IFN-γ)/lipopolysaccharide (LPS) (11) . Northern and Western blotting experiments demonstrated that both iNOS mRNA and protein levels increased as muristerone A or ponasterone A was increased (data not shown).
We used these NO-generating cells as a tool to study the effect of NO on tumor growth. Microencapsulation techniques have been used to entrap NO-generating cells within a semipermeable alginate-poly-L-lysine membrane (12) .
The average diameter of the microcapsules is 400 ± 100 µm (Fig. 1A) . This technique allows small molecules such as nutrients and oxygen to freely diffuse into the cell and, more important, will allow NO to diffuse out while preventing attack from the host immune system. Microencapsulated EcR293 clone 11 sub-1 cells can survive in vitro for at least 3 wk. Moreover, the encapsulated cells can generate NO in a controlled fashion upon stimulation with ponasterone A or muristerone A at concentrations from 1 to 10 µM. This NO activity is completely inhibited by the NOS inhibitor L-NIO. To evaluate NO generation, 10-20 microencapsulated cells were plated in 6-well plates, and NO was detected by using the Griess reaction (Fig. 1B) . On the second day after induction, the measurable nitrite level was approximately 6 µM. This level rises to 50 µM on day 4. When ponasterone A was removed and the cells were washed with PBS, the cells were "switched off." Cells could be "switched on" again by reapplication of ponasterone A at a concentration of 10 µM (Fig. 1B) . NO can be readily detected by using the NO-sensitive fluorescent probe DAF-2 DA (10) (Fig. 1D ). Uninduced cells showed very little fluorescence (data not shown), whereas NO-generating microencapsulated cells produced very strong fluorescence 2 days postinduction (Fig. 1C, D) .
Inhibition of tumor cell growth in vivo by microencapsualtion of iNOS-expressing cells
A xenograft nude mouse model was used to assess the ability of microencapsulated cells to inhibit tumor cell growth in vivo. To produce subcutaneous tumors in female CD 1 nude mice, DLD-1 cells (1 × 10 6 /mouse) were injected subcutaneously along with microencapsulated EcR293 clone 11 sub-1 cells (5 × 10 6 cells). The mean diameter of tumors was measured with calipers two or three times a week. Tumor volume was estimated by using the following formula: tumor volume = length × width 2 × 2.54. Tumors obtained from each of the experiments were frozen in liquid nitrogen for subsequent analysis by Western blotting or enzyme assay or for histological evaluation. The results are shown in Fig. 2A (data represent at least three experiments). The results demonstrate that DLD-1 tumors in the presence of NO-generating microencapsulated cells were significantly smaller (257 ± 150 mm 3 , 28 days after subcutaneous injection) compared with control tumors that were not generating NO (480 ± 143 mm 3 ) . NO generation resulted in a 54% reduction in tumor volume (Student's t test, P<0.05). In control experiments, microencapsulated EcR293 cells were shown to be incapable of forming tumors, either in the presence of ponasterone A or in its absence, as has been reported for the parental cell line HEK293 (13) . The NOS enzyme activities of four tumors from day 10 postimplantation were 223 ± 56 pmol/min/mg, whereas the NOS enzyme activity in five control tumors (uninduced) was undetectable. NOS enzyme activity was diminished 14 days postimplantation, to 40 ± 15 pmol/min/mg. To overcome this time-dependent inactivation of ponasterone A in vivo, further injections of ponasterone A were made at tumor sites in five mice at 2 mg/mouse/wk after 14 days. Using this treatment resulted in a further reduction of DLD-1 tumor size to 142 ± 110 mm 3 after 30 days of induction with ponasterone A.
In separate control experiments, microencapsulated EcR293 clone 11 sub-1 cells alone were injected subcutaneously into a panel of 10 nude mice. Mice were examined after 30 days, and none of the animals showed any evidence of tumor growth at the injection site. In a series of further control experiments, unencapsulated EcR293 clone 11 sub-1 cells were injected subcutaneously into nude mice. These cells were also unable to form tumors in a panel of 20 nude mice, even at very high cell numbers (2 × 10 7 cells/mouse). It is important that HEK 293 cells have been used in a variety of gene therapy protocols (14, 15) and have been validated for use in humans in a recent phase I clinical trial (14) .
In separate control experiments, DLD-1 tumors (1 × 10 6 cells) were grown in nude mice (n = 5) in the presence of ponasterone A (1 mg/mouse). The rates of tumor growth were indistinguishable from DLD-1 tumors alone (data not shown), suggesting that ponasterone A has no measurable effect on tumor growth. To support these findings, we examined Fas and FasL mRNA levels in our muristerone Ainducible cells in vitro (Fig. 3A) . Treatment of EcR293 clone 11 sub-1 cells with muristerone A resulted in the generation of NO and a concomitant 3.3 ± 0.5-fold increase in FasL mRNA and a 4.5 ± 1.5-fold increase in Fas mRNA as compared with untreated cells (Fig. 3B ). This result was further supported by transient transfection experiments with human Fas and FasL promoterluciferase fusion constructs. The activity of a 1.7-kb human Fas promoter (17) increased more than twofold following NO generation (Fig. 3C ) after the addition of 10 µM muristerone A.
Interestingly, previous work has demonstrated (17) the presence of an Sp1-NF-kβ binding motif at -295 to -286 of the promoter that is mainly responsible for PMA/ionomycin (P/I) induction.
To determine whether this element is also responsive to NO-mediated regulation, we used a construct containing six copies of the kβ-Sp1 (K/S6tk-Luc) element (−295 to -286) upstream of a thymidine kinase-driven luciferase cassette. This construct was transiently transfected into EcR293 clone 11 sub-1 cells. Treatment with 10 µM muristerone A resulted in a more than twofold increase in luciferase activity (Fig. 3D) , supporting the hypothesis that this element plays a role in NO-enhanced promoter activity. Reporter fusion experiments were also carried out with a 1.5-kb human FasL promoter element (18) . After transient transfection into EcR293 clone 11 sub-1 cells, the activity of the human FasL promoter increased more than twofold after muristerone A induction (Fig. 3E ).
Administration of tetracycline or doxycycline to suppress tumor growth
Although the insect hormone ecdysone and its synthetic analogues muristerone A and ponasterone A have no reported effects on mammalian cells, they have not yet been evaluated in human safety trials. To make our NO-generating microencapsulated cells more acceptable for human use, an alternative induction system based on tetracycline was selected for further study. Tetracycline has been used in humans for decades and therefore represents a good orally bioavailable inducer. For this series of experiments, we cloned a 4-kb human iNOS cDNA sequence into a tetracycline-regulated mammalian expression vector pcDNA/TO (Invitrogen). A panel of 25 cell lines was isolated showing tetracycline-dependent (10 ng/ml) induction of NO. One of the clones, Tex293 clone 22, can generate up to 100 µM nitrite/10 6 cells in 24 h. This induction can be completely inhibited by addition of the NOS inhibitor L-NIO (20 µM).
Northern and Western blotting experiments demonstrated that both iNOS mRNA and protein levels are increased as the tetracycline concentration is increased (data not shown).
To test the efficiency of Tex293 clone 22 cells in tumor cell-killing experiments, we cocultured both DLD-1 and SKOV-3 cells with Tex293 clone 22 cells. We mixed together 10 6 DLD-1 cells and 2 × 10 6 Tex293 clone 22 cells and seeded them overnight into 6-well plates. In separate experiments, 10 6 SKOV-3 cells and 3 × 10 6 Tex293 clone 22 cells were mixed together and seeded into 6-well plates. After overnight growth, tetracycline (10 ng/ml) was added to the medium to induce cells to generate NO. Two control groups were set up: one group of cocultured cells received no tetracycline, and the other received 20 µM L-NIO concomitantly with tetracycline. NO generation was greatly elevated in the tetracycline group, and this increase was inhibited by L-NIO (Fig. 4A) . After 3 days of culture, trypan blue exclusion staining and lactate dehydrogenase (LDH) assays were used to evaluate cell viability (Fig. 4B) . After tetracycline treatment, cell death greater than 80% was detected in both DLD-1/Tex293 clone 22 and SKOV-3/Tex293 clone 22 groups by LDH analysis. In contrast, control groups not receiving tetracycline showed only 15% cell death. Similarly, control groups treated with tetracycline in the presence of the NOS inhibitor L-NIO showed only 30% cell death. Results of viability experiments are also shown for Tex293 clone 22 alone (Fig. 4C), DLD-1 cells (Fig.  4D) , DLD-1/Tex293 clone 22 cells cocultured without induction (Fig. 4E) , and DLD-1/Tex293 clone 22 cells cocultured with tetracycline induction (Fig. 4F) , in which NO-mediated cell killing was apparent. Western blotting carried out on protein samples from these wells showed that both Fas and FasL proteins were also significantly up-regulated in both DLD-1/Tex293 clone 22 and SKOV3/Tex293 clone 22 NO-generating cells (Fig. 4G) , and this increase could be attenuated by adding the NOS inhibitor L-NIO (20 µM).
More than 45% of the tetracycline-induced DLD-1/clone 22 cocultured cells underwent apoptosis detectable by the TUNEL method (Fig. 4H) , whereas uninduced cells showed only 10% apoptosis in the same assay. Incubation with 2.5 µg/ml Fas(human)-Ig:Fc chimeric molecule (Alexis) at the time of induction partially inhibited tetracycline-induced apoptotic cell death, with only 22% of cells showing nuclear fragmentation, which is statistically significant (Student's t test, P<0.05) compared with uninduced cocultures. This level of nuclear fragmentation was still much higher than that seen after administration of the NOS inhibitor L-NIO (20 µM), which resulted in only 12% of cells showing TUNEL-positive staining. Incubation with a Fas:Fc chimeric molecule clearly resulted in only partial inhibition of apoptosis and may suggest that other signal transduction pathways may also be involved in NOmediated tumor killing. To support this hypothesis, previous work has shown that members of the tumor necrosis factor family, such as Trail, may also be unregulated by NO (16) and act as a signal to the apoptotic pathway.
To determine whether established tumor growth can be reversed by treatment with iNOSexpressing cells, we tested the cells in a mouse xenograft model. Tex293 clone 22 cells were microencapsulated as described above and then injected adjacent to the site of preestablished DLD-1 tumors. These tumors had been implanted 7-10 days previously (2 × 10 6 DLD-1 tumor cells/mouse) and had grown to between 50 and 100 mm 3 cells/mouse). Doxycycline was maintained in the drinking water, and this treatment resulted in the maintenance of tumor growth inhibition for another month, with an average of tumor volume of 100 ± 86 at 56 days (Fig. 5B) . The control group of mice, carrying the same number of DLD-1 cells but not receiving doxycycline, were killed at day 45. Doxycycline-treated DLD-1 tumor animals were killed after a further 30 days and showed no remaining tumor histology, with only encapsulated cell material being detectable. It is important that histological examination of host tissue flanking the site of microencapsulated cell implantation showed no overt damage, suggesting that the NO-mediated effect on cell viability is tumor specific. Using Tex293 clone 22 iNOS-expressing cells to treat SKOV-3 tumors produced similar results (Fig. 5C ).
In control experiments with Tex293 clone 22 microencapsulated cells, NO was shown to be generated in vivo at the tumor site by using an amiNO-700 NO sensor (inNO-T, the NOmeasuring system with temperature compensation) after precalibration with sodium nitrite (Fig.  6) . NO was measured in situ in tumor sites 5 days after induction with doxycycline; uninduced control mice had basal levels of NO (100 ± 25 nM NO/min, averaged from three uninduced tumors), whereas induced mice produced 210 ±15 nM NO/min (averaged from three induced tumors). These measurements showed a statistically significant higher NO production (Student's t test, P<0.01) in induced cells. To test the long-term viability of microencapsulation, cells were implanted in the flank of nude mice and were dissected out 1 month later. The resulting cells were cultured in 6-well plates and were tested for their ability to generate NO. Treatment with tetracycline resulted in the accumulation of 20 µM nitrite/10 6 cells/ml/24 h.
DISCUSSION
In this paper, we described a novel method to produce human cells capable of generating high concentrations of NO under the control of two inducible promoters, responsive to both the insect hormone ecdysone and its analogues and tetracycline and its analogues. Our results demonstrate that microencapsulated iNOS-expressing cells can be successfully used to inhibit tumor growth. It should be noted that the NOS activity in our two inducible promoter systems is comparable to NOS activity measured in murine macrophages activated by treatment with IFN-γ and LPS (11) , which have been demonstrated to possess antitumor activity (2) . In a previous study, we reported the surprising finding that DLD-1 human carcinoma cells transfected with a murine iNOS cDNA cassette (iNOS-19 cells) actually resulted in increased tumor cell growth (19) . The iNOS expression constructs reported here result in considerably higher NOS activity than that reported for the iNOS-19 clone. For example, iNOS-19 cells generated 20 pmol/min/mg NOS activity, whereas the same number of clone 11 sub-1 cells (20 µM ponasterone A induction) and clone 22 cells (10 ng/ml tetracycline induction) resulted in 300 pmol/min/mg activity. This level of expression is also one order of magnitude greater than retrovirally transfected human carcinoma cells, such as cau-6 and HT29 (20) . It appears that high levels of iNOS expression may be cytostatic or cytotoxic for tumor cells, whereas lower activity can have the opposite effect and promote tumor growth and neovascularization and provide radiation resistance and multidrug resistance through up-regulation of DNA-PKcs (9, 19, 20) . NO is a relatively unstable molecule that can potentially form reactive nitrogen species such as ONOO − , and these reactive nitrogen species may play more important roles in tumor biology than NO itself.
The dramatic elimination of SKOV-3 and DLD-1 tumors by microencapsulated iNOS-expressing cells demonstrates the therapeutic potential for this approach. This cell-based delivery system has the added safety feature of generating NO only after the oral administration of tetracycline.
Fas-mediated apoptosis is an important mechanism for the regulation of tumor cell viability, and recent reports have shown that many ovarian carcinoma cell lines are Fas/FasL positive and consequently are susceptible to Fas-mediated apoptosis (21) . We show that NO can up-regulate both Fas and FasL in tumor cells, and this result is in agreement with previous findings that NO can sensitize ovarian tumor cells by up-regulating Fas gene expression, resulting in apoptosis (5) . NO has also been shown to trigger apoptosis in freshly isolated human leukemic lymphocytes by up-regulating both FasL and Trail and activating caspase 8-mediated apoptosis (16) . Histological evaluation of tissue samples from our in vivo tumor experiments suggests that the NO-mediated killing is highly specific for tumor cells. Previous work has shown that although FasL was present on melanoma cells, it was absent from host melanocytes, suggesting differential regulation during tumorigenesis (22) .
Mechanistically, we also demonstrated for the first time that the iNOS-directed tumor killing is associated with regulation of the Fas/FasL cell death pathway. It is possible that the high levels of NO and related reactive nitrogen species generated by our microencapsulated iNOSexpressing cells may trigger the up-regulation of Fas, FasL, and related proteins in target tumors, resulting in the activation of apoptotic pathways. The approach described here could have the potential to inhibit or kill many different types of tumors of various histological origins, which are sensitive to the Fas/FasL death pathway. Overall, the differential regulation of Fas/FasL in tumor cells by NO compared with normal cells may well represent an important mechanism of differential killing. The kβ-Sp1 enhancer element was required for NO-mediated Fas promoter activity. Six copies of the kβ-Sp1 element (−295 to −286) were juxtaposed upstream of a thymidine kinasedriven luciferase reporter gene and transiently transfected into EcR293 clone 11 sub-1 cells. Luciferase activity was more than doubled after treatment with 10 µM muristerone A. E) Transient transfection of EcR293 clone 11 sub-1 with a human FasL promoter-luciferase construct. Luciferase activity was more than doubled after treatment with 10 µM muristerone A. Values in C, D, and E are means (± SD) from three separate experiments. **P < 0.01. The relative luciferase activities were calculated as described (9) after cotransfection of the promoter-reporter plasmid and the internal control plasmid pRL-tk. were implanted in the flank of a nude mouse and were grown for 7 days. Microencapsulated cells were implanted adjacent to the established tumor, and NO was induced by the administration of 0.5 mg/ml doxycycline in the drinking water (in 1% ethanol, ). In the control group, mice received vehicle only (1%, ). All mice were treated for 30 days with drug (changed two or three times per week) or vehicle alone. Each point represents the mean (± SD) for 10 mice. B) Second injection of microencapsulated Tex293 clone 22 cells into the remaining five DLD-1 tumor sites. Each point represents the mean (± SD) for five mice. C) The use of microencapsulated Tex293 clone 22 cells to treat established SKOV-3 tumors. SKOV-3 cells (5 × 10 5 ) were implanted in the flank of a nude mouse and were grown for 10 days. The microencapsulated cells were implanted adjacent to the established tumor, and NO was induced by the administration of 0.5 mg/ml doxycycline in the drinking water (in 1% ethanol, ). In the control group, mice received vehicle only (1%, ). All mice were treated for 30 days with drug (changed two or three times per week) or vehicle alone. Each point represents the mean (± SD) for six mice. 6 . In situ measurements of NO release from a tumor site by using an amiNO-700 probe. The sensor was inserted into the subcutaneous site of tumors in nude mice, and recoding was started. Control groups included uninduced preestablished tumors with 1% ethanol in the drinking water (no inducer), whereas the tumor 1 and tumor 2 samples were 5-day samples with doxycycline (0.5 mg/ml) in the drinking water.
